Daily Newsletter

20 November 2023

Daily Newsletter

20 November 2023

Bayer announces recall of cancer therapy Vitrakvi in US

Vitrakvi is intended for treating NTRK gene fusion-positive solid tumours.

Vishnu Priyan November 20 2023

Bayer has announced a voluntary recall of a single lot of its cancer therapy Vitrakvi (larotrectinib) oral solution 20mg/mL, available in 100mL glass bottles.

The consumer-level recall comes after the company detected cases of microbial contamination with Penicillium brevicompactum during routine stability inspections.

Vitrakvi treats NTRK gene fusion-positive solid tumours. Patients receiving the drug may therefore already be immunocompromised. 

Penicillium brevicompactum has not been found to impact human pathology in the literature, but cases of invasive disease have been reported to be caused by such Penicillium species, especially in those with underlying immunosuppression. 

In a press statement, Bayer said: “Therefore, there is a reasonable probability that ingestion of Penicillium brevicompactum in patients on Vitrakvi with underlying immunosuppression may result in invasive fungal infections of the blood or pneumonia that can be life-threatening. 

“To date, Bayer has not received any adverse events related to this recall.”

The company asked anyone who has the recalled product lot to cease its usage immediately and reach out to their physician or healthcare provider if they face any issues or have queries.

Bayer is issuing this product recall with the US Food and Drug Administration’s knowledge.

The company has informed all distributors and pharmacies of the latest update and has selected Qualanex to handle the product recall at the consumer level. 

Qualanex has notified distributors of Vitrakvi via a recall notification letter. The company will make arrangements for distributors, consumers and pharmacies to return the recalled product lot. 

Any adverse reactions or quality-related issues encountered following the usage of Vitrakvi can be notified to the MedWatch Adverse Event Reporting programme of the FDA either online, by mail or by fax.

Acute Renal Failure (ARF) - Market Landscape

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.